HPLC Reference Standard for API Impurity and Stability Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for evaluating the quality and stability of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid, a therapeutic agent for metabolic diseases, are inadequate due to variations in retention times and the need for reliable reference standards to quantify impurities and active pharmaceutical ingredients.
Innovation Solution
A related substance, represented by Chemical Formula 2, is synthesized and used as a reference standard to evaluate the quality and stability of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid through HPLC and other chromatographic methods, allowing for precise determination of impurities and active ingredient content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the active pharmaceutical ingredient is used as a reference standard for quality evaluation, then the analysis can be performed using available materials, but the excessive proportion of the active ingredient saturates the chromatography column resulting in irreproducible retention time
Solution Approach 1:
The patent creates a synthetic copy (Chemical Formula 2) that replicates the key structural features of the active pharmaceutical ingredient (Chemical Formula 1) but with modified properties. This synthetic reference standard mimics the chromatographic behavior of the API without causing column saturation, thereby resolving the contradiction between using available materials and achieving reproducible measurements
Solution Approach 2:
The patent modifies specific parameters of the reference standard structure - changing the carboxylic acid group to an ester group and adjusting the molecular weight by adding a methyl group. These parameter changes allow the reference standard to maintain similar chromatographic retention characteristics while avoiding the saturation problem that occurs with the pure API
2Reliability
If HPLC analysis is performed to measure active pharmaceutical ingredient content and impurities, then quality control can be achieved, but variations in equipment conditions and other factors cause retention time variations affecting accurate impurity identification
Solution Approach 1:
The patent introduces a synthetic reference standard (Chemical Formula 2) as an intermediary substance that serves as a stable benchmark for retention time comparison. This intermediary provides a consistent reference point that is not affected by the same variability issues as the API itself, enabling more accurate impurity identification despite equipment condition variations
Solution Approach 2:
The patent establishes a feedback mechanism where the synthetic reference standard's consistent retention time serves as a reference against which all other peaks are compared. This feedback loop allows for real-time correction and identification of impurities by comparing their retention times relative to the stable reference, compensating for systematic variations in the HPLC system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables accurate qualitative and quantitative analysis of the pharmaceutical product, ensuring compliance with quality criteria under various storage conditions by using Chemical Formula 2 as a reference standard, thereby stabilizing the evaluation process.
Implementation Method 1
evaluating the content of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid in the pharmaceutical product
Data Source
AI summary
The present invention provides a related substance of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid, and a method for evaluating the quality of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en yl)benzyloxy)phenyl)hex-4-inoic acid using the same. According to the present invention, it is possible to evaluate the quality, stability and the like of a pharmaceutical composition comprising (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid using a compound of Chemical Formula 2 or a salt thereof as a reference standard.